3SBio Inc. announced that the Company's Recombinant Human Thrombopoietin Injection (TPIAO®) submitted for the treatment of persistent or chronic primary immune thrombocytopenia (ITP) in children or adolescents to the National Medical Products Administration (NMPA) of the PRC have been approved on 2 April. TPIAO ® is the Recombinant Human Thrombopoietin Injection independently developed by 3SBio, which has previously been approved for solid tumor post-chemotherapy thrombocytopenia (CIT) and primary immune thrombocytopenia (ITP) indications in adults. Currently, the Recombinant Human Thrombopoietin Injection is the first-choice second-line treatment drug recommended by PRC's ITP guidelines.

Primary immune thrombocytopenia (ITP) is an acquired autoimmune hemorrhagic disease. Pediatric ITP is often characterized by sudden petechiae, ecchymosis or bleeding in children who are normally healthy. Occasionally, thrombocytopenia is found in patients who undergo whole blood cell counts due to other conditions.

In order to meet the clinical treatment needs of pediatric ITP and respond to the national call to develop drugs for children, 3SBio launched its Phase III clinical study for pediatric ITP in a total of 10 children's hospitals and general hospitals across the country, with the overall effective rate as the main therapeutic efficacy index.